KVUE:NYSE
Kenvue Inc
18,01 $
arrow_upward
+1,41%(+0,25) 1 d.
18,01 $
0,00% (0,00)
bedtimePēctirdzniecības
Slēgts: 14. okt., 16:00:05 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: KVUE…
Atvērt
17,92 $
Augsta
18,04 $
Zema
17,76 $
Tirgus kapitalizācija
34,59 mljrd.
Vid. apjoms
24,20 milj.
Apjoms
27,61 milj.
Dividende
4,66%
Ceturkšņa dividendes
0,21 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 21. sept.
Cenas/peļņas attiecība
20,88
Augstākā 52 ned.
20,13 $
Zemākā 52 ned.
14,02 $
Peļņa uz vienu akciju
0,86 $
Beta
0,48
Apgrozībā esošās akcijas
1,92 mljrd.
Darbinieku skaits
22 tūkst.
Atvērt
17,92 $
Augsta
18,04 $
Zema
17,76 $
Tirgus kapitalizācija
34,59 mljrd.
Vid. apjoms
24,20 milj.
Apjoms
27,61 milj.
Dividende
4,66%
Ceturkšņa dividendes
0,21 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 21. sept.
Cenas/peļņas attiecība
20,88
Augstākā 52 ned.
20,13 $
Zemākā 52 ned.
14,02 $
Peļņa uz vienu akciju
0,86 $
Beta
0,48
Apgrozībā esošās akcijas
1,92 mljrd.
Darbinieku skaits
22 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
News Corp
·
pirms 5 stundām
Kenvue Inc. stock rises Wednesday, outperforms market
CNBC
·
pirms 1 dienas
We're adding to a consumer staples stock in advance of a big catalyst
Reuters
·
pirms 1 dienas
EU approves Kimberly-Clark's $40 billion Kenvue acquisition
News Corp
·
pirms 1 dienas
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
Profils
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
Par “Kenvue Inc”
ĢenerāldirektorsKirk Perry
Darbinieki21,9 tūkst.
Dibināšanas datums2022
Galvenais birojsSummit, Ņūdžersija, Amerikas Savienotās Valstis
SektorsPersonal care products
Tīmekļa vietnekenvue.com